KingstronBio

KingstronBio (also known as Jinshi Biology) is a Chinese medical device company specializing in the research, development, and manufacturing of innovative products for structural heart disease. Founded in 2012 and headquartered in Suzhou, China, the company's extensive product portfolio includes artificial bioprosthetic heart valves, valve annuloplasty rings, cardiac surgical biopatches, and transcatheter valve systems. KingstronBio is a pioneer in dry-valve technology, having developed the world's first pre-loaded dry transcatheter aortic valve replacement (TAVR) system, Prostyle A®, which received NMPA approval in 2025. Leveraging its proprietary Micro-Ex™ anti-calcification and AirBo™ dry storage technologies, the company aims to provide highly durable, safe, and ready-to-use solutions for patients with valvular heart diseases such as aortic stenosis and mitral regurgitation.